PY2076934A - Compuesto cannabinoide de tipo cannabidiol - Google Patents
Compuesto cannabinoide de tipo cannabidiolInfo
- Publication number
- PY2076934A PY2076934A PY202002076934A PY2076934A PY2076934A PY 2076934 A PY2076934 A PY 2076934A PY 202002076934 A PY202002076934 A PY 202002076934A PY 2076934 A PY2076934 A PY 2076934A PY 2076934 A PY2076934 A PY 2076934A
- Authority
- PY
- Paraguay
- Prior art keywords
- cbd
- cannabidiol
- cannabinoid
- cannabinoid compound
- type
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/348—Cannabaceae
- A61K36/3482—Cannabis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
- C07C37/68—Purification; separation; Use of additives, e.g. for stabilisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1916846.7A GB201916846D0 (en) | 2019-11-19 | 2019-11-19 | Cannabidiol-type cannabinoid compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PY2076934A true PY2076934A (es) | 2021-07-15 |
Family
ID=69063341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PY202002076934A PY2076934A (es) | 2019-11-19 | 2020-11-19 | Compuesto cannabinoide de tipo cannabidiol |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12396963B2 (https=) |
| EP (1) | EP4061342A1 (https=) |
| JP (1) | JP7664242B2 (https=) |
| KR (1) | KR20220103757A (https=) |
| CN (1) | CN114727972A (https=) |
| AU (1) | AU2020385666A1 (https=) |
| CA (1) | CA3156758A1 (https=) |
| GB (2) | GB201916846D0 (https=) |
| MX (2) | MX2022005933A (https=) |
| PY (1) | PY2076934A (https=) |
| TW (1) | TW202132247A (https=) |
| WO (1) | WO2021099777A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2487712B (en) | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| GB2514054A (en) | 2011-09-29 | 2014-11-12 | Gw Pharma Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2560019A (en) | 2017-02-27 | 2018-08-29 | Gw Res Ltd | Use of cannabinoids in the treatment of leukaemia |
| GB2564383B (en) | 2017-06-23 | 2021-04-21 | Gw Res Ltd | Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex |
| GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB201910389D0 (en) | 2019-07-19 | 2019-09-04 | Gw Pharma Ltd | Novel compounds, methods for their manufacture, and uses thereof |
| GB2588576A (en) | 2019-08-27 | 2021-05-05 | Gw Res Ltd | Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease |
| GB201916849D0 (en) | 2019-11-19 | 2020-01-01 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
| GB201916846D0 (en) | 2019-11-19 | 2020-01-01 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
| GB201916974D0 (en) | 2019-11-21 | 2020-01-08 | Gw Res Ltd | Cannabidol-type cannabinoid compound |
| GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| GB2597321A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB202013765D0 (en) | 2020-09-02 | 2020-10-14 | Gw Res Ltd | Method of preparing cannabinoids |
| GB2602019A (en) | 2020-12-15 | 2022-06-22 | Gw Res Ltd | Cannabinoid derivative as a pharmaceutically active compound and method of preparation thereof |
| AU2023321655A1 (en) | 2022-08-12 | 2025-02-13 | Jazz Pharmaceuticals Research Uk Limited | Oral solid dosage forms comprising cannabinoids |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001003690A1 (en) * | 1999-07-12 | 2001-01-18 | Virginia Commonwealth University | Novel vasodilator cannabinoid analogs |
| US10538373B2 (en) | 2002-08-14 | 2020-01-21 | Gw Pharma Limited | Pharmaceutical formulation |
| GB2456183A (en) | 2008-01-04 | 2009-07-08 | Gw Pharma Ltd | Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
| GB2471987B (en) | 2008-06-04 | 2012-02-22 | Gw Pharma Ltd | Anti-tumoural effects of cannabinoid combinations |
| GB2478595B (en) | 2010-03-12 | 2018-04-04 | Gw Pharma Ltd | Phytocannabinoids in the treatment of glioma |
| TWI583374B (zh) | 2010-03-30 | 2017-05-21 | Ｇｗ伐瑪有限公司 | 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途 |
| US10441617B2 (en) | 2013-03-15 | 2019-10-15 | Biotech Institute, Llc | Breeding, production, processing and use of medical cannabis |
| ES2525137B1 (es) * | 2013-06-13 | 2016-01-18 | Servicio Andaluz De Salud | Agentes para tratar el mieloma múltiple |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2527599A (en) | 2014-06-27 | 2015-12-30 | Gw Pharma Ltd | Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy |
| GB2531281A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531280A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| MX395015B (es) | 2014-12-12 | 2025-03-24 | Ojai Energetics Pbc | Composiciones microencapsuladas de cannabinoides |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2541191A (en) | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2548873B (en) | 2016-03-31 | 2020-12-02 | Gw Res Ltd | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome |
| GB2551985B (en) | 2016-07-01 | 2019-01-30 | Gw Res Ltd | Novel formulation |
| GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2553139A (en) | 2016-08-25 | 2018-02-28 | Gw Res Ltd | Use of cannabinoids in the treatment of multiple myeloma |
| IL248149B (en) | 2016-09-29 | 2020-03-31 | Garti Nissim | Dilutable formulations of cannbinoids and processes for their preparation |
| IL248150B (en) * | 2016-09-29 | 2018-05-31 | Garti Nissim | Method for selective extraction of cannabinoids from a plant source |
| GB2557921A (en) | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
| GB2559774B (en) | 2017-02-17 | 2021-09-29 | Gw Res Ltd | Oral cannabinoid formulations |
| WO2018205022A1 (en) | 2017-05-08 | 2018-11-15 | Inmed Pharmaceuticals Inc. | Ocular drug delivery formulation |
| GB2564383B (en) | 2017-06-23 | 2021-04-21 | Gw Res Ltd | Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex |
| EP3687527A4 (en) * | 2017-09-25 | 2021-05-26 | Canopy Health Innovations | COMPOSITIONS OF CANNABIDIOL, TETRAHYDROCANNABINOL, TERPENS AND FLAVONOIDS AND THEIR USES FOR TREATMENT OF INSOMNIA |
| GB201715919D0 (en) | 2017-09-29 | 2017-11-15 | Gw Res Ltd | use of cannabinoids in the treatment of epilepsy |
| GB2568471B (en) | 2017-11-15 | 2022-04-13 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| US11179340B2 (en) * | 2017-12-29 | 2021-11-23 | TGC Network LLC | Cannabidiol dosage form |
| GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
| GB2572125B (en) | 2018-01-03 | 2021-01-13 | Gw Res Ltd | Pharmaceutical |
| GB2572126B (en) | 2018-01-03 | 2021-01-13 | Gw Res Ltd | Pharmaceutical |
| GB2572737A (en) | 2018-01-24 | 2019-10-16 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| US10751380B2 (en) * | 2018-03-08 | 2020-08-25 | Alexander Kariman | Compound and method for treating spasms, inflammation and pain |
| GB201806953D0 (en) | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
| GB201807942D0 (en) * | 2018-05-16 | 2018-06-27 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| GB2579179A (en) | 2018-11-21 | 2020-06-17 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
| GB2580881A (en) | 2018-11-30 | 2020-08-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2580653A (en) | 2019-01-21 | 2020-07-29 | Gw Res Ltd | Use of cannabinoids in the treatment of comorbidities associated with epilepsy |
| GB2581517A (en) | 2019-02-22 | 2020-08-26 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2581987B (en) | 2019-03-06 | 2021-11-17 | Gw Res Ltd | Use of cannabidiol in combination with antibiotics |
| GB2584140A (en) | 2019-05-23 | 2020-11-25 | Gw Res Ltd | Use of cannabidiol in the treatment of epileptic spasms |
| GB2584341B (en) | 2019-05-31 | 2023-03-01 | Gw Res Ltd | Cannabinoid formulations |
| GB201910389D0 (en) | 2019-07-19 | 2019-09-04 | Gw Pharma Ltd | Novel compounds, methods for their manufacture, and uses thereof |
| GB2586026A (en) | 2019-07-29 | 2021-02-03 | Gw Res Ltd | Use of cannabidol in the treatment of Dravet syndrome |
| GB2588576A (en) | 2019-08-27 | 2021-05-05 | Gw Res Ltd | Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease |
| GB2588460A (en) | 2019-10-25 | 2021-04-28 | Gw Res Ltd | Use of cannabidiol preparations in the treatment of temporal lobe epilepsy |
| GB201916846D0 (en) | 2019-11-19 | 2020-01-01 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
| GB201916849D0 (en) | 2019-11-19 | 2020-01-01 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
| GB201916977D0 (en) | 2019-11-21 | 2020-01-08 | Gw Res Ltd | Cannibidol-type cannabinoid compound |
| GB201916974D0 (en) | 2019-11-21 | 2020-01-08 | Gw Res Ltd | Cannabidol-type cannabinoid compound |
| GB201918846D0 (en) | 2019-12-19 | 2020-02-05 | Gw Res Ltd | Oral cannabinoid formulations |
| GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| GB2597318A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597306A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597312A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597309A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597315A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597281A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to brain injury |
| GB2597323A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597279A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
| GB2597316A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597308A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
| GB2597317A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597301A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with herpes simplex virus |
| GB2597285A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2600077A (en) | 2020-07-20 | 2022-04-27 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597322A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597321A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597313A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597311A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB202013765D0 (en) | 2020-09-02 | 2020-10-14 | Gw Res Ltd | Method of preparing cannabinoids |
| GB202014250D0 (en) | 2020-09-10 | 2020-10-28 | Gw Res Ltd | Use of cannabidivarin in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| US20220087951A1 (en) | 2020-09-18 | 2022-03-24 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| GB2598922A (en) | 2020-09-18 | 2022-03-23 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
| GB2601755A (en) | 2020-12-08 | 2022-06-15 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with epilepsy syndromes |
| GB2602019A (en) | 2020-12-15 | 2022-06-22 | Gw Res Ltd | Cannabinoid derivative as a pharmaceutically active compound and method of preparation thereof |
| GB2602020A (en) | 2020-12-15 | 2022-06-22 | Gw Res Ltd | A method for evaluating the pro- or anti convulsive properties of test compounds |
| TW202237554A (zh) | 2020-12-15 | 2022-10-01 | 英商吉偉研究有限公司 | 新穎化合物、其製備方法及其用途 |
| GB2606334A (en) | 2021-02-12 | 2022-11-09 | Gw Res Ltd | Use of cannabidivarin in the treatment of seizures associated with canine epilepsy |
| ES3058168T3 (en) | 2021-05-12 | 2026-03-09 | Jazz Pharmaceuticals Research Uk Ltd | Resorcinol derivative as a pharmaceutically active compound and method of preparation thereof |
| KR20240007921A (ko) | 2021-05-12 | 2024-01-17 | 지더블유 리서치 리미티드 | 레조르시놀, 이의 제조 방법, 및 이의 용도 |
| CN117295706A (zh) | 2021-05-12 | 2023-12-26 | 吉伟研究有限公司 | 用于治疗癫痫的大麻二酚-c4的衍生物 |
| US11815187B2 (en) | 2022-01-26 | 2023-11-14 | Maag Germany Gmbh | 3-port valve |
-
2019
- 2019-11-19 GB GBGB1916846.7A patent/GB201916846D0/en not_active Ceased
-
2020
- 2020-11-18 JP JP2022529060A patent/JP7664242B2/ja active Active
- 2020-11-18 MX MX2022005933A patent/MX2022005933A/es unknown
- 2020-11-18 US US17/777,734 patent/US12396963B2/en active Active
- 2020-11-18 WO PCT/GB2020/052938 patent/WO2021099777A1/en not_active Ceased
- 2020-11-18 KR KR1020227020505A patent/KR20220103757A/ko active Pending
- 2020-11-18 CN CN202080079589.2A patent/CN114727972A/zh active Pending
- 2020-11-18 CA CA3156758A patent/CA3156758A1/en active Pending
- 2020-11-18 GB GB2018129.3A patent/GB2590793B/en not_active Expired - Fee Related
- 2020-11-18 AU AU2020385666A patent/AU2020385666A1/en active Pending
- 2020-11-18 EP EP20812408.1A patent/EP4061342A1/en active Pending
- 2020-11-18 TW TW109140412A patent/TW202132247A/zh unknown
- 2020-11-19 PY PY202002076934A patent/PY2076934A/es unknown
-
2022
- 2022-05-16 MX MX2025005109A patent/MX2025005109A/es unknown
-
2025
- 2025-07-24 US US19/279,169 patent/US20260041698A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3156758A1 (en) | 2021-05-27 |
| JP7664242B2 (ja) | 2025-04-17 |
| EP4061342A1 (en) | 2022-09-28 |
| GB2590793B (en) | 2022-10-26 |
| KR20220103757A (ko) | 2022-07-22 |
| GB201916846D0 (en) | 2020-01-01 |
| US20260041698A1 (en) | 2026-02-12 |
| US12396963B2 (en) | 2025-08-26 |
| AU2020385666A1 (en) | 2022-05-26 |
| US20230022487A1 (en) | 2023-01-26 |
| CN114727972A (zh) | 2022-07-08 |
| GB2590793A (en) | 2021-07-07 |
| GB202018129D0 (en) | 2020-12-30 |
| JP2023503068A (ja) | 2023-01-26 |
| MX2025005109A (es) | 2025-06-02 |
| MX2022005933A (es) | 2022-06-22 |
| WO2021099777A1 (en) | 2021-05-27 |
| TW202132247A (zh) | 2021-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PY2076934A (es) | Compuesto cannabinoide de tipo cannabidiol | |
| PY2076926A (es) | Compuesto cannabinoide de tipo cannabidiol | |
| PY2076940A (es) | Compuesto cannabinoide de tipo cannabidiol | |
| PY2076931A (es) | Compuesto cannabinoide de tipo cannabidiol | |
| EA202191427A1 (ru) | Каннабиноидное соединение типа каннабидиола | |
| PY2068174A (es) | Compuesto cannabinoide | |
| CL2020000632A1 (es) | Composición y método para el tratamiento del autismo. | |
| CO2017008437A2 (es) | Métodos de purificación de cannabinoides, composiciones y kits de los mismos | |
| MX2017015304A (es) | Plantas de cannabis que tienen expresion modificada de acido tetrahidrocannabinolico sintasa. | |
| CL2020003373A1 (es) | Composición y método de ahorro de opiáceos | |
| CL2007000525A1 (es) | Método para aumentar el rendimiento de semillas de plantas que consiste en aumentar la expresión de una secuencia de ácido nucleico que codifica un dominio del factor de transcripción del polipéptido myb; método de producción de planta transgénica; y uso de la secuencia de ácido nucleico para aumentar el rendimiento de semillas de plantas. | |
| BR112015007295A2 (pt) | processo para a preparação de compostos; compostos; e uso dos mesmos | |
| MX2023009882A (es) | Anticuerpos anti-muc1-c y estructuras car-t. | |
| BR112017010555A2 (pt) | composições e métodos para produção de polipeptídeos com padrão de glicosilação modificado em células vegetais | |
| BR112012023623A2 (pt) | agentes osmóticos de polissacarídeos esterificados | |
| BR112018007801A2 (pt) | processo para produção de glicóis. | |
| BR112015008539A2 (pt) | micro-esferas compreendendo carotenóides | |
| CO2021001059A2 (es) | Composición de cannabinoides y método para tratar el ptsd y/o la ansiedad | |
| MX2024002431A (es) | Estabilizacion mejorada de ficocianinas en composiciones acidas. | |
| BR112016002079A2 (pt) | Processo para preparação de um aditivo ácido de oximorfona, solução aquosa de aditivo ácido de oximorfona, aditivo ácido de oximorfona sólido, e, alcaloide de oximorfona sólido | |
| PE20212081A1 (es) | Planta de stevia con baja formacion de polen | |
| UY35808A (es) | Proceso para micropropagación in vitro de material de planta y proceso para la producción, a gran escala y elevado volumen, de mudas clonales de plantas listas para su desarrollo en campo | |
| CO2023013545A2 (es) | Supresión de nematodos | |
| PY2068167A (es) | Compuesto cannabinoide | |
| PY2068171A (es) | Compuesto cannabinoide |